Global Diabetic Nephropathy Market Size, Pharmaceuticals, Research, Experiments

Posted by Deeksha on February 11th, 2019

The global market status for Diabetic Nephropathy is precisely examined through a smart research report added to the broad database managed by Market Research Hub (MRH). This study is titled “Global Diabetic Nephropathy Market” Size, Status and Forecast 2019-2025, which tends to deliver in-depth knowledge associated to the Diabetic Nephropathy market for the present and forecasted period until 2025. Furthermore, the report examines the target market based on market size, revenue and geography; making it quite useful for the readers.

Get Sample Copy of This Report @

Diabetic nephropathy is a disease of the kidney glomerulus and one of the most significant complications in terms of mortality and morbidity for patients with diabetes. Diabetic nephropathy is mainly characterized by macroalbuminuria. The presence of over 300 milligrams of albumin in the urine in 1 day is known as macroalbuminuria. Globally, the diabetic nephropathy market is witnessing significant growth due to rise in the incidence of diabetes and obesity in different regions of the world. In addition, increasing R&D investments in drug discovery and development by various companies, such as Sanofi, Eli Lilly and Mitsubishi Tanabe Pharma is also driving the growth of the market.

North America has the largest market for the global diabetic nephropathy market. However, In terms of growth, Asia is the fastest growing region. Disease Modifying Therapies (DMT) is the largest and fastest growing mode of treatment, whereas ACE inhibitors, is the largest and fastest growing DMT of diabetic nephropathy.

Growing prevalence of diabetes and obesity, increasing R&D investments in drug discovery and development, and rising awareness about diabetes and kidney-related disorders are some of the major drivers of the diabetic nephropathy market. On the other hand, stringent regulatory requirements and longer approval time for drugs as well as a lack of comprehensive therapeutic management for diabetic nephropathy are major concerns for the market. Increasing usage of combination therapy is gaining popularity in diabetic nephropathy market is the recent market trends that have been observed in diabetic nephropathy market.

In 2018, the global Diabetic Nephropathy market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

This report focuses on the global Diabetic Nephropathy status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Diabetic Nephropathy development in United States, Europe and China.

The key players covered in this study
Abbott Laboratories
Eli Lilly
Reata Pharmaceuticals
Mitsubishi Tanabe Pharma

Market segment by Type, the product can be split into
ACE Inhibitors
Calcium Channel Blockers(CCBs)
Renin Inhibitors
Connective Tissue Growth Factor (CTGF) Inhibitors
Antioxidant Inflammation Modulators(AIMs)
Monocyte Chemoattractant Protein (MCP)Inhibitors
Endothelin-A Receptor(ETAR)Antagonist
G Protein-Coupled Receptors (GPCRs)

Market segment by Application, split into
Cancer Research Institutes
Diagnostic Labs

Market segment by Regions/Countries, this report covers
United States
Southeast Asia
Central & South America


Like it? Share it!


About the Author

Joined: January 3rd, 2019
Articles Posted: 12,334

More by this author